Ragweed Allergy (Seasonal Allergic Rhinitis)

Cliantha Research, Clinical Research Organization (CRO)

The purpose of this study is to assess the onset of action and effectiveness of DYMISTA® nasal spray in relieving your nasal and ocular allergy symptoms caused by ragweed pollen in an Environmental Exposure Unit/Chamber (EEC).

Eligibility Criteria

Female, Male

18 to 55 years old

At least a 2-year medical history of allergy to ragweed

Not have current diagnosis of asthma

Not have received ragweed immunotherapy within the last 6 months

Other inclusion/exclusion criteria will be assessed

Study Tasks

Informed Consent Document (ICF)
Medical history and demographic data
Measurement of vital signs and physical examination
Skin prick test (SPT) to show positivity to ragweed allergen
Spirometry to test lung function
Exposure to ragweed pollen in an Environmental Exposure Chamber (EEC)
COVID-19 screening/testing


This study has been approved by Advarra Ethics Board


Clinical trial
Ragweed Allergy
Nasal allergies

Activity and Time

Investigational Medicine

Clinical Trial

Weekdays, Weekends

56 days total, 5 sessions

After the initial phone screening, in-clinic general screening will be conducted to confirm allergy to ragweed (compensation of $50 upon completion of visit procedures) and other procedures. Participants who screen pass general screening will be eligible to continue to the medical screening visit.


Up to $2325

Study Address

4500 Dixie Rd Mississauga, Ontario, Canada, L4W 1N2

Posting date: Dec 16, 2020

Earn $2325